0
Skip to Content
Context Therapeutics
About
Pipeline
Patients
Careers
Investors & News
Context Therapeutics
About
Pipeline
Patients
Careers
Investors & News
About
Pipeline
Patients
Careers
Investors & News

News

Publications Martin Lehr 4/28/25 Publications Martin Lehr 4/28/25

Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3

Stanley Roberts, Kelly Byrnes-Blake, and Eric Butz

American Association for Cancer Research I Annual Meeting I Abstract 4884 I April 26-30, 2025

Read More

About Us
Leadership
Partnering
Contact Us

Pipeline
CTIM-76
CT-95
CT-202

Patients
Clinical Trials
Investigator Led Trials
Access Policy

Investors & Media
News

Careers
Open Positions

Privacy Policy          Terms of Use

© Context Therapeutics Inc. 2025  |  All Rights Reserved